Levels of soluble cell adhesion molecules in patients with dyslipidemia

Circulation. 1996 Apr 1;93(7):1334-8. doi: 10.1161/01.cir.93.7.1334.

Abstract

Background: Increased expression of cell adhesion molecules (CAMs) on the vascular endothelium has been postulated to play an important role in atherogenesis. Both in vitro and in vivo studies have suggested that dyslipidemia may increase expression of CAMs.

Methods and results: To determine whether dyslipidemia is associated with increased expression of CAMs, we examined the levels of soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule 1 (sVCAM-1), and soluble E-selectin (sE-selectin) in individuals with either hypercholesterolemia or hypertriglyceridemia and in control subjects matched for age and sex. Patients with hypertriglyceridemia had significantly higher levels of sVCAM-1 (739 +/- 69 ng/mL) compared with patients with hypercholesterolemia (552 +/- 63 ng/mL) and control subjects (480 +/- 56 ng/mL). Levels of sICAM-1 were significantly increased in both the hypercholesterolemic and hypertriglyceridemic groups (298 +/- 29 and 342 +/- 31 ng/mL, respectively) compared with the control group (198 +/- 14 ng/mL). Levels of sE-selectin were significantly increased in hypercholesterolemic patients (74 +/- 9 ng/mL) compared with control subjects (48 +/- 5 ng/mL). Ten hypercholesterolemic patients were treated aggressively with atorvastatin alone or a combination of colestipol and either atorvastatin or simvastatin for a mean of 42 weeks and had an average LDL cholesterol reduction of 51%. Comparison of soluble CAMs before and after treatment showed a significant reduction only in sE-selectin (77 +/- 11 versus 56 +/- 6 ng/mL, P < or = .03) but not for sVCAM-1 or sICAM-1.

Conclusions: Although severe hyperlipidemia is associated with increased levels of soluble CAMs, aggressive lipid-lowering treatment had only limited effects on the levels. Increased levels of soluble CAMs in patients with hyperlipidemia may be a marker for atherosclerosis.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anticholesteremic Agents / therapeutic use
  • Arteriosclerosis / blood
  • Arteriosclerosis / epidemiology
  • Atorvastatin
  • Cell Adhesion Molecules / blood*
  • Colestipol / administration & dosage
  • Colestipol / therapeutic use
  • Drug Therapy, Combination
  • E-Selectin / blood
  • Endothelium, Vascular / metabolism
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Heptanoic Acids / administration & dosage
  • Heptanoic Acids / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypercholesterolemia / blood*
  • Hypercholesterolemia / drug therapy
  • Hypertriglyceridemia / blood*
  • Hypolipidemic Agents / therapeutic use
  • Intercellular Adhesion Molecule-1 / blood
  • Lovastatin / administration & dosage
  • Lovastatin / analogs & derivatives
  • Lovastatin / therapeutic use
  • Male
  • Middle Aged
  • Pyrroles / administration & dosage
  • Pyrroles / therapeutic use
  • Risk Factors
  • Simvastatin
  • Solubility
  • Vascular Cell Adhesion Molecule-1 / blood

Substances

  • Anticholesteremic Agents
  • Cell Adhesion Molecules
  • E-Selectin
  • Enzyme Inhibitors
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Pyrroles
  • Vascular Cell Adhesion Molecule-1
  • Intercellular Adhesion Molecule-1
  • Lovastatin
  • Atorvastatin
  • Simvastatin
  • Colestipol